Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lene Ryom

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|March 14, 2025
The potential for annual long-acting HIV pre-exposure prophylaxisLene Ryom
The Lancet. HIV|September 24, 2016
The benefits and risks of PrEP and kidney functionAmanda Mocroft, Lene Ryom
Current Opinion in Infectious Diseases|December 13, 2017
Contemporary protease inhibitors and cardiovascular riskJens Lundgren, Amanda Mocroft, Lene Ryom
Current HIV/AIDS Reports|February 29, 2012
HIV therapies and the kidney: some good, some not so good?Lene Ryom, Amanda Mocroft, Jens Lundgren
The European Respiratory Journal|March 5, 2026
Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implicationsChristian Kraef, Lene Ryom, Ole Kirk, et al.
Current Opinion in HIV and AIDS|November 15, 2013
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive personsLene Ryom, Amanda Mocroft, Jens D Lundgren
Expert Opinion on Drug Safety|May 28, 2021
Cardiovascular risks associated with protease inhibitors for the treatment of HIVCamilla Ingrid Hatleberg, Lene Ryom, Caroline Sabin
Current Opinion in HIV and AIDS|August 24, 2017
Are we successfully managing cardiovascular disease in people living with HIV?Camilla I Hatleberg, Jens D Lundgren, Lene Ryom
The Lancet. HIV|December 24, 2022
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk - Authors' replyBastian Neesgaard, Lauren Greenberg, Lars Peters, et al.
Current HIV/AIDS Reports|May 1, 2016
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent DevelopmentsAmit C Achhra, Melinda Nugent, Amanda Mocroft, et al.
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|March 14, 2025
The potential for annual long-acting HIV pre-exposure prophylaxisLene Ryom
The Lancet. HIV|September 24, 2016
The benefits and risks of PrEP and kidney functionAmanda Mocroft, Lene Ryom
Current Opinion in Infectious Diseases|December 13, 2017
Contemporary protease inhibitors and cardiovascular riskJens Lundgren, Amanda Mocroft, Lene Ryom
Current HIV/AIDS Reports|February 29, 2012
HIV therapies and the kidney: some good, some not so good?Lene Ryom, Amanda Mocroft, Jens Lundgren
The European Respiratory Journal|March 5, 2026
Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implicationsChristian Kraef, Lene Ryom, Ole Kirk, et al.
Current Opinion in HIV and AIDS|November 15, 2013
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive personsLene Ryom, Amanda Mocroft, Jens D Lundgren
Expert Opinion on Drug Safety|May 28, 2021
Cardiovascular risks associated with protease inhibitors for the treatment of HIVCamilla Ingrid Hatleberg, Lene Ryom, Caroline Sabin
Current Opinion in HIV and AIDS|August 24, 2017
Are we successfully managing cardiovascular disease in people living with HIV?Camilla I Hatleberg, Jens D Lundgren, Lene Ryom
The Lancet. HIV|December 24, 2022
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk - Authors' replyBastian Neesgaard, Lauren Greenberg, Lars Peters, et al.
Current HIV/AIDS Reports|May 1, 2016
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent DevelopmentsAmit C Achhra, Melinda Nugent, Amanda Mocroft, et al.
Pageof 11